[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599072":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":24,"centralContacts":33,"locations":41,"responsibleParty":73,"collaborators":76,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":81,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":24,"studyType":93,"phases":94,"briefSummary":97,"conditions":98,"keywords":24,"overallStatus":44,"whyStopped":24,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Columbia University","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Letermovir","EXPERIMENTAL","Patients with moderate to high risk CMV risk will get letermovir for prophylaxis for 6 months for moderate risk and 1 year for high risk",[13],"Drug: Letermovir",{"label":15,"type":16,"description":17,"interventionNames":18},"Valganciclovir","ACTIVE_COMPARATOR","Patients with moderate to high risk CMV risk will get valganciclovir for prophylaxis for 6 months for moderate risk and 1 year for high risk. This is standard of care",[19],"Drug: Valganciclovir",{"label":21,"type":22,"description":23,"interventionNames":24},"No treatment","NO_INTERVENTION","Low risk CMV patients who do not have an indication for CMV prophylaxis will be monitored",null,[26,30],{"type":27,"name":9,"description":28,"armGroupLabels":29,"otherNames":24},"DRUG","CMV prophylaxis",[9],{"type":27,"name":15,"description":31,"armGroupLabels":32,"otherNames":24},"Standard therapy for CMV prophylaxis",[15],[34,39],{"name":35,"role":36,"phone":37,"phoneExt":24,"email":38},"Afsana Rahman, MD","CONTACT","2123054600","ar3262@cumc.columbia.edu",{"name":40,"role":36,"phone":24,"phoneExt":24,"email":24},"Adel T Alnatour, BS",[42,63],{"facility":43,"status":44,"city":45,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"NYP-Weill Cornell","RECRUITING","New York","10021","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-74.00597,40.71427,{"lat":53,"lon":52},[56,60,61],{"name":57,"role":36,"phone":58,"phoneExt":24,"email":59},"David Majure, MD","6469629062","dtm9002@med.cornell.edu",{"name":40,"role":36,"phone":24,"phoneExt":24,"email":24},{"name":57,"role":62,"phone":24,"phoneExt":24,"email":24},"PRINCIPAL_INVESTIGATOR",{"facility":64,"status":44,"city":45,"state":45,"zip":65,"country":47,"countryCode":48,"cosmosGeoPoint":66,"geoPoint":68,"contacts":69},"Columbia University\u002FNYP Milstein Hospital","10032",{"type":50,"coordinates":67},[52,53],{"lat":53,"lon":52},[70,71,72],{"name":35,"role":36,"phone":37,"phoneExt":24,"email":38},{"name":40,"role":36,"phone":24,"phoneExt":24,"email":24},{"name":35,"role":62,"phone":24,"phoneExt":24,"email":24},{"type":62,"investigatorFullName":74,"investigatorTitle":75,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Afsana Rahman","Assistant Professor of Medicine",[77],{"name":78,"class":6},"Cornell University","100599072","phase-2-valganciclovir-vs-letermovir-for-cmv-prophylaxis-in-heart-transplant-100599072",false,"NCT07079735","Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant","VALganciclovir vs. LETermovir for Primary Prevention of CMV in Moderate to High-Risk Heart Transplant Recipients (The VALET-CMV Study)","VALET-CMV","Inclusion Criteria:\n\nPatients who are \\>18 years of age who have received a heart transplant and have not started their CMV prophylaxis regimen will be included.\n\nExclusion Criteria:\n\nHistory of or suspected CMV disease within 6 months prior is excluded.","ALL","18 Years","99 Years",{"count":91,"type":92},150,"ESTIMATED","INTERVENTIONAL",[95,96],"PHASE2","PHASE3","The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.",[99,100,101],"CMV Viremia","Heart Transplant Infection","Heart Transplant Failure and Rejection","2025-09-22",{"date":104,"type":105},"2025-09-25","ACTUAL",{"date":107,"type":105},"2025-09-12",{"date":109,"type":92},"2029-01-17",{"name":5,"class":6},2]